tiprankstipranks
Trending News
More News >

Aethlon Medical Reports Q4 Financial Results and Achievements

Story Highlights
Aethlon Medical Reports Q4 Financial Results and Achievements

Don’t Miss TipRanks’ Half-Year Sale

Aethlon Medical ( (AEMD) ) just unveiled an announcement.

On June 26, 2025, Aethlon Medical announced its financial results for the fiscal fourth quarter ended March 31, 2025, highlighting significant operational achievements and clinical progress. The company treated three patients in its Hemopurifier cancer trial in Australia and received regulatory approval in India to initiate a similar study. Aethlon also reduced operating expenses by 26% through streamlined operations, positioning itself for sustained focus on clinical and regulatory goals. The company is advancing research on the Hemopurifier’s potential applications in Long COVID and other diseases, with collaborations and preclinical studies supporting broader uses.

The most recent analyst rating on (AEMD) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.

Spark’s Take on AEMD Stock

According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.

Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.

To see Spark’s full report on AEMD stock, click here.

More about Aethlon Medical

Aethlon Medical, Inc. is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Average Trading Volume: 76,435

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.16M

For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1